Looking to sell Abridge stock or options?
Abridge has developed a healthcare application aimed at enhancing the clarity and comprehension of medical discussions. This app leverages machine learning to provide an audio-based platform that records and summarizes conversations between patients and doctors. By delivering insights and context, it empowers users to adhere to medical advice and stay informed about their health.
Leonis Investissement, NVentures (Santa Clara), Whistler Capital Partners, Pillar VC, Elad Gil, Mayo Clinic, Union Square Ventures, Mana Ventures, ApSTAT Technologies, American College of Cardiology Foundation, University of California, Spark Capital, Irvine, Kaiser Permanente Ventures, LifePoint Health, KdT Ventures, UPMC Enterprises, Zen Chu, Nvidia, Mass General Brigham, CVS Health Ventures, Gaingels, IKS Health, CapitalG, Wittington Ventures.
Abridge is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Abridge stock. Depending on Abridge’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Abridge stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Abridge stock in two ways. First, Abridge employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Abridge stock. Note that all transactions in Abridge shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Abridge stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Abridge stock. Typically, shares of private companies like Abridge are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Feb 2024, Abridge is reported to have closed an equity financing in which the investors valued the company at $845M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Abridge shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Abridge is not currently publicly traded, it does not have a ticker symbol.
Abridge has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Abridge is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Abridge shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
"Discover how OpenNotes and Beth Israel Deaconess Medical Center are partnering with Abridge, an AI platform, to improve patient communications and outcomes. Le
According to Research by SNS Insider, Growing demand for accurate documentation, value-based care, and integration of AI-powered CDI solutions propels...
Years before ChatGPT emerged, Rao founded Abridge to automate medical notetaking with large language models
Discover how Abridge, an AI clinical documentation startup, is reportedly raising $250M to reach a $2.5B valuation. Learn about its health system clients here.
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Suki just grabbed fresh funding from Hedosophia to beat out Abridge in the healthcare AI race. See the 17-slide pitch deck it used to raise the cash.
Experts think more private equity deals in healthcare are on the way after R1 RCM's $8.9 billion acquisition.
"Discover how Reid Health is revolutionizing patient care with Abridge's generative AI technology, resulting in increased efficiency and improved documentation
The three companies will collaborate with Mayo Clinic nurses to create a genAI documentation workflow tool that will integrate into Epic nursing workflows.
Ask any of the health-focused VCs to name one of the top AI startups and one name comes up over and over again: a company based in Pittsburgh called